2015

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy FA, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M; Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.   AIDS. 2015 Jan 14;29(2):193-200

2014

Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.   AIDS. 2014 Jun 1;28(9):1351-6

Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Lodi S, Dray-Spira R, Touloumi G, Braun D, Teira R, D'Arminio Monforte A, Gallois A, Zangerle R, Spire B, Dabis F, Stähelin C, Termote M, Kirk O, Chêne G, Egger M, del Amo J.   AIDS. 2014 Sep 24;28(15):2297-306

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.   Clin Infect Dis. 2014 May;58(9):1312-21.

2013

The incidence of AIDS-defining illnesses at a current CD4 count ? 200 cells/?L in the post-combination antiretroviral therapy era. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD.   Clin Infect Dis. 2013 Oct;57(7):1038-47.

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE),   J Infect Dis. 2013 Mar 1;207(5):759-67.

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE),   J Infect Dis. 2013 Mar 1;207(5):759-67.

Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.   PLoS Med. 2013;10(9):e1001510.

2012

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. Pursuing Later Treatment Options II (PLATO II) project team; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group,   A. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Pursuing Later Treatment Option II (PLATO II) project team; Observational HIV Epidemiological Research Europe (COHERE) Group,   Lancet Infect Dis. 2012 Feb;12(2):119-27.

2011

The MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.   BMC Infect Dis. 2011 Jan 25;11(1):23.

European multicohort study. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): x   a Lancet Infect Dis. 2011 Feb 25.

2010

The PLATO II Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group Triple class virologic failure in HIV-infected patients on antiretroviral therapy for up to 10 years   Archives of Internal Medicine 2010 Mar 8;170(5):410-419.

Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?   Infect Dis. 2010 Sep 1;51(5):611-9.

2009

Collaboration of MASTER Cohort and ARCA Cohort.Effectiveness of Antiretroviral Regimens Containing Abacavir with Tenofovir in Treatment-Experienced Patients: Predictors of Virological Response and Drug Resistance Evolution in a Multi-Cohort Study.   Infection. 2009 Aug 7.

UCSC cohort; MASTER cohort; ARCA cohort. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.   Infection. 2009 Oct;37(5):438-44.

2008

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age.   AIDS. 2008 Jul 31;22(12):1463-73.

2004

Collaboration of HIV Cohorts. Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound.   The Journal of Infectious Diseases 2004; 190:675-687.

The PLATO Collaboration. Predictors of CD4 count trend and mortality among HIV-1 infected persons with virologic failure to all three antiretroviral drug classes. .   The Lancet 2004; 364:51-62

Vedi tutto